A First-in-Man Study of the Firesorb BVS (FUTURE-I)

Inclusion Criteria: 1. 18-75 years of age, males or non-pregnant females; 2. With silent ischemia evidence, patients with stable or unstable angina, or in patients with old myocardial infarction; 3. Total number of target lesion is 1; 4. Target lesion length ≤ 25mm (Visual); target lesion diameter between 3.0mm to 3.5mm; 5. Visual assessment of target lesion diameter stenosis ≥ 70%,TIMI blood flow≥1; 6. Each target lesion may be covered by a single stent; 7. Patients with indications for coronary artery bypass graft surgery; 8. To understand the purpose of testing, voluntary and informed consent, patients undergoing invasive imaging follow-up. Exclusion Criteria: 1. Within 1 week of any acute myocardial infarction or myocardial enzymes did not return to normal; 2. Implantation of stent in target vessel within 1 year , patients with planned intervention again within six months; 3. Severe congestive heart failure (NYHA class III and above) ,left ventricular ejection fraction or \<40% (ultrasound or left ventricular angiography); 4. Preoperative renal function serum creatinine \>2.0mg/DL; receiving hemodialysis; 5. Bleeding, active gastrointestinal ulcers, brain hemorrhage or subarachnoid hemorrhage and half year history of ischemic stroke, antiplatelet agents and would not allow an anticoagulant therapy contraindications patients undergoing antithrombotic therapy; 6. Aspirin, clopidogrel, heparin, contrast agent, poly lactic acid polymer and rapamycin allergies; 7. The patient's life expectancy is less than 12 months; 8. Top participated in other drug or medical device and does not meet the primary study endpoint in clinical trials time frame; 9. Researchers determine patient compliance is poor, unable to complete the study in accordance with the requirements; 10. Heart transplantation patients; 11. The unstable arrhythmia, such as high risk ventricular extrasystole and ventricular tachycardia; 12. Cancer need chemotherapy; 13. Immunosuppression and autoimmune diseases, planned or undergoing immunosuppressive therapy; 14. Planning or being receiving long-term anticoagulant therapy, such as heparin, warfarin, etc; 15. Within six months for elective surgery requires stopping aspirin, Clopidogrel patients; 16. Blood test prompted platelet counts of less than 100x10E9/L or greater than 700x10E9/L, white blood cells than 3x10E9/L; known or suspected liver disease (such as hepatitis); 17. Peripheral vascular disease, 6F catheter is not available.